ArticleBritish journal of pharmacology2014

Luteolin is effective in the non-small cell lung cancer model with L858R/T790M EGF receptor mutation and erlotinib resistance.

Zhuan Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.